GI
AGIO icon

Gradient Investments’s Agios Pharmaceuticals AGIO Stock Holding History

Gradient Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22
Closed -$490 – 1247
2023
Q4 		$490 Hold
22
– – ﹤0.01% 1599
2023
Q3 		$545 Hold
22
– – ﹤0.01% 1535
2023
Q2 		$623 Buy
+22
New +$547 ﹤0.01% 1497

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gradient Investments's AGIO Position: Q1 2024 in Review

Gradient Investments sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 22 shares — an estimated $490 sold.

Gradient Investments first reported a position in AGIO in Q2 2023 and held it in 3 quarters. The position peaked at $623 in Q2 2023. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

  • Gradient Investments reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 22 Agios Pharmaceuticals shares in Q1 2024, an estimated $490.
  • Gradient Investments first reported a position in Agios Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Gradient Investments's Agios Pharmaceuticals position peaked at $623 in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.